|Day Low/High||46.74 / 47.86|
|52 Wk Low/High||38.80 / 85.83|
-- Mallinckrodt Reaffirms Industry-Leading Commitment to Ensuring Safe and Appropriate Use of its Specialty Generic Opioid Products --
-- R&D-Focused Event to Highlight Commercial Portfolio and Growing Pipeline --
-- Long Hospital Stays, Frequent Medical Visits and Hospital Readmissions Drive Costs, Payer Burden --
Individual state investigations of opioid marketing practices has lead to a multistate investigation of the prescription painkiller industry.
--Mallinckrodt's PENNANT Trial to Assess Efficacy and Safety of H.P. Acthar Gel in ALS Patients--
-- Trial to Assess Efficacy and Safety in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements --
Wall Street wasn't able to extend a record-breaking streak into a third session on Monday after a terror attack in London.
Wall Street couldn't extend a record-breaking steak into a third session following the weekend terror attack in London.
Stocks are mostly lower on Monday after a terror attack in London over the weekend and following a rare analyst downgrade on Apple shares.
Citron attacked Mallinckrodt's partnership with Express Scripts ESRX, liking it to the role specialty prescription company Philidor played for embattled pharma company Valeant.
Shares of drug maker Mallinckrodt were falling Wednesday afternoon
The unit accounted for about 30% of the company's revenue in the first quarter.
More competition could help overcome the suspicion over drug prices that plagues the would-be business partners' dealings.
-- Preliminary Demographic Data on Currently Enrolled Patients to be Presented at the 2017 Annual Meeting of the Consortium of Multiple Sclerosis Centers [Poster RT01] --
-- Mallinckrodt's OPTIONS Trial to Assess Efficacy and Safety of H.P. Acthar Gel in Patients with Relapsing-Remitting Multiple Sclerosis --
Kynikos Associates' James Chanos, famous for his shorting campaign at Enron, on Thursday presented a short campaign.
-- Mallinckrodt's Trial to Assess Safety, Tolerability, and Efficacy as an Alternative to Autografting Full-thickness Complex Skin Defects --
A look at Trump's first 100 days in office in 140 characters or less.
-- Results of treating physician survey suggest treatment with H.P. Acthar® Gel (repository corticotropin injection) among patients with infantile spasms may reduce medical resource utilization, including emergency room visits, hospitalizations and days hospitalized [Poster 219] --
Doug Kass shares his thoughts on Apple, Allergan and Western Digital.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.